+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Nifedipine Market 2021-2025

  • PDF Icon

    Report

  • 50 Pages
  • July 2021
  • Region: China
  • China Research & Intelligence
  • ID: 5393438
Nifedipine is a dihydropyridine calcium channel blocker, which is mainly used to bind to L-type calcium channels. Nifedipine is mainly used to treat chronic stable angina pectoris, vasospasm angina pectoris (angina pectoris, variant angina pectoris) and essential hypertension. Nifedipine was developed by Bayer AG, and Bayer AG's Nifedipine is traded under the name ADALAT. By 2020, there are several manufacturers in China's Nifedipine market, among which Bayer AG has the highest market share in sales value.

According to the analyst's market research, the sales value of Nifedipine in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of Covid-19 on the overall medical diagnosis and treatment services, the sales value of Nifedipine in the Chinese market fell to CNY730 million, and the CAGR of Nifedipine from 2016 to 2020 was 4.42%.

The analyst expects that with the relief of Covid-19, the sales value of Nifedipine in the Chinese market will have a restorative growth from 2021 to 2025. In addition, in recent years, nearly 20 million people worldwide died of cardiovascular and cerebrovascular diseases caused by hypertension and coronary heart disease each year. An estimated 300 million patients live with high blood pressure in China. As ageing of population in China becomes increasingly severe, the number and prevalence of patients are increasing year by year. Therefore, there is an increasing trend in sales volume of Nifedipine for the treatment of angina and hypertension. At the same time, compared with similar drugs, Nifedipine has longer action time, fewer doses, more stable blood concentrations, and less toxic and side effects. Based on these advantages, the sales volume and sales value of Nifedipine in the Chinese market will continue to grow from 2021 to 2025.

Topics Covered:

  • The impact of COVID-19 on China's Nifedipine market
  • Sales value of China's Nifedipine 2016-2020
  • Competitive landscape of China's Nifedipine market
  • Prices of Nifedipine in China
  • Prices of Nifedipine in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Nifedipine market
  • Prospect of China's Nifedipine market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Nifedipine
1.1 Indications for Nifedipine
1.2 Development of Nifedipine in China
1.3 Governmental Approval of Nifedipine in China
1.4 The Impact of COVID-19 on Nifedipine sales in China
2 Sales of Nifedipine in China, 2016-2020
2.1 Sales Value of Nifedipine
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Nifedipine
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Nifedipine by Dosage Form in China, 2016-2020
2.3.1 Controlled Release Tablets
2.3.2 Tablets
2.3.3 Sustained Release Tablets
2.3.4 Soft Capsules
3 Analysis of Major Nifedipine Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Nifedipine Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Bayer AG
3.2.1 Enterprise Profile
3.2.2 Sales of ADALAT (Bayer AG’s Nifedipine) in China
3.3 Shanghai Shyndec Pharmaceutical Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Xinran (Shanghai Shyndec Pharmaceutical Co., Ltd.’s Nifedipine) in China
3.4 Qingdao Huanghai Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Maikaofen (Qingdao Huanghai Pharmaceutical Co., Ltd.’s Nifedipine) in China
3.5 Beijing Honglin Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Nifuda (Beijing Honglin Pharmaceutical Co., Ltd.’s Nifedipine) in China
3.6 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Shansu (Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.’s Nifedipine) in China
4 Prices of Nifedipine for Different Manufacturers in China, 2020-2021
4.1 Bayer AG (ADALAT)
4.2 Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
4.3 Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
4.4 Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
4.5 Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd. (Shansu)
5 Prospect of Chinese Nifedipine Market, 2021-2025
5.1 Influential Factors of Chinese Nifedipine Market Development
5.1.1 The Impact of COVID-19 on Chinese Nifedipine Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
List of Charts
Chart Patent Information About Nifedipine Controlled Release Tablets Registration in China
Chart Patent Information About Nifedipine Tablets Registration in China
Chart Patent Information About Nifedipine Sustained Release Tablets Registration in China
Chart Patent Information About Nifedipine Soft Capsules Registration in China
Chart Sales Value of Nifedipine Controlled Release Tablets over the World
Chart Sales Value of Nifedipine Tablets over the World
Chart Sales Value of Nifedipine Sustained Release Tablets over the World
Chart Sales Value of Nifedipine Soft Capsules over the World
Chart Sales Value of Nifedipine Controlled Release Tablets in China, 2016-2020
Chart Sales Value of Nifedipine Tablets in China, 2016-2020
Chart Sales Value of Nifedipine Sustained Release Tablets in China, 2016-2020
Chart Sales Value of Nifedipine Soft Capsules in China, 2016-2020
Chart Sales Value of Nifedipine Controlled Release Tablets in China by Region, 2016-2020
Chart Sales Value of Nifedipine Tablets in China by Region, 2016-2020
Chart Sales Value of Nifedipine Sustained Release Tablets in China by Region, 2016-2020
Chart Sales Value of Nifedipine Soft Capsules in China by Region, 2016-2020
Chart Sales Volume of Nifedipine Controlled Release Tablets in China, 2016-2020
Chart Sales Volume of Nifedipine Tablets in China, 2016-2020
Chart Sales Volume of Nifedipine Sustained Release Tablets in China, 2016-2020
Chart Sales Volume of Nifedipine Soft Capsules in China, 2016-2020
Chart Sales Volume of Nifedipine Controlled Release Tablets in China by Region, 2016-2020
Chart Sales Volume of Nifedipine Tablets in China by Region, 2016-2020
Chart Sales Volume of Nifedipine Sustained Release Tablets in China by Region, 2016-2020
Chart Sales Volume of Nifedipine Soft Capsules in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Nifedipine Controlled Release Tablets Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Nifedipine Tablets Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Nifedipine Sustained Release Tablets Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Nifedipine Soft Capsules Manufacturers in China, 2016-2020
Chart Sales Value and Volume of ADALAT in China, 2016-2020
Chart Sales Value and Volume of Xinran in China, 2016-2020
Chart Sales Value and Volume of Maikaofen in China, 2016-2020
Chart Sales Value and Volume of Nifuda in China, 2016-2020
Chart Sales Value and Volume of Shansu in China, 2016-2020
Chart Referential Prices of ADALAT in China by Region, 2020-2021
Chart Referential Prices of Xinran in China by Region, 2020-2021
Chart Referential Prices of Maikaofen in China by Region, 2020-2021
Chart Referential Prices of Nifuda in China by Region, 2020-2021
Chart Referential Prices of Shansu in China by Region, 2020-2021
Chart Forecast on Sales Value of Nifedipine Controlled Release Tablets in China, 2021-2025
Chart Forecast on Sales Value of Nifedipine Tablets in China, 2021-2025
Chart Forecast on Sales Value of Nifedipine Sustained Release Tablets in China, 2021-2025
Chart Forecast on Sales Value of Nifedipine Soft Capsules in China, 2021-2025
Chart Forecast on Sales Volume of Nifedipine Controlled Release Tablets in China, 2021-2025
Chart Forecast on Sales Volume of Nifedipine Tablets in China, 2021-2025
Chart Forecast on Sales Volume of Nifedipine Sustained Release Tablets in China, 2021-2025
Chart Forecast on Sales Volume of Nifedipine Soft Capsules in China, 2021-2025

Samples

Loading
LOADING...

Companies Mentioned

  • Bayer AG (ADALAT)
  • Shanghai Shyndec Pharmaceutical Co., Ltd. (Xinran)
  • Qingdao Huanghai Pharmaceutical Co., Ltd. (Maikaofen)
  • Beijing Honglin Pharmaceutical Co., Ltd. (Nifuda)
  • Yangtze River Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.(Shansu)

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Table Information